The FDA will allow Xellia to begin packaging and labeling work at the former Boehringer Ingelheim plant that the Denmark company bought last year to expand its sterile manufacturing capacity. Xellia has added 90 employees and will add 80 more as it preps to start production at the facility in 2018.
